The following is a Practice Update interview with Dr Hans Hammers, Associate Professor, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. During this interview, Dr Hammers talks about the upcoming combination therapies for the treatment of metastatic renal cell carcinoma (mRCC), such as nivolumab/ipilimumab, axitinib/pembrolizumab, cabozantinib/nivolumab, tivozanib/nivolumab and bevacizumab/atezolizumab combinations currently in development. The clinical trials mentioned during Dr Hammers’s interview were presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference held in San Francisco last week.

See Dr Hammers’s interview on Practice Update here